# Sara A. Hurvitz

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sara-a-hurvitz/

## Facts

| Field | Value |
| --- | --- |
| Citations | 32,230 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 77 |
| i10-index | 252 |
| Last Known Institution | University of Washington |
| OpenAlex ID | https://openalex.org/A5068059897 |
| ORCID iD | https://orcid.org/0000-0001-7808-7191 |
| Works | 711 |

## Researcher papers

- [Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation](https://scholariq.org/papers/talazoparib-in-patients-with-advanced-breast-cancer-and-a-germline-i-brca-i/)
- [Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer/)
- [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://scholariq.org/papers/esmo-clinical-practice-guideline-for-the-diagnosis-staging-and-treatment-of/)
- [Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer](https://scholariq.org/papers/tucatinib-trastuzumab-and-capecitabine-for-her2-positive-metastatic-breast/)
- [Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial](https://scholariq.org/papers/intracranial-efficacy-and-survival-with-tucatinib-plus-trastuzumab-and/)
- [Cycling cancer persister cells arise from lineages with distinct programs](https://scholariq.org/papers/cycling-cancer-persister-cells-arise-from-lineages-with-distinct-programs/)
- [NCCN Guidelines® Insights: Breast Cancer, Version 4.2023](https://scholariq.org/papers/nccn-guidelines-insights-breast-cancer-version-4-2023/)
- [Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer](https://scholariq.org/papers/biomarker-analyses-in-the-phase-iii-ascent-study-of-sacituzumab-govitecan-versus/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [University of Washington](https://scholariq.org/institutions/university-of-washington/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.